FDA staff sees no major concerns for Grail's multi-cancer blood test
US FDA staff reviewers did not raise major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers. The findings on the screening test, called Galleri, will be discussed at the FDA's external advisers' meeting on Wednesday to review Grail's request for premarket approval.